Literature DB >> 11493769

Mechanisms governing bone metastasis in prostate cancer.

M L Cher1.   

Abstract

Why does prostate cancer metastasize to bone? Why is there increased turnover of the bone matrix in the presence of prostate cancer? A recent autopsy study supports a traditional hypothesis that gross, anatomic patterns of blood flow influence the distribution of metastatic deposits. On the other hand, recent developments in animal models of prostate cancer bone metastasis have renewed interest in the traditional 'seed and soil' hypothesis: several studies point to specific biological interactions between prostate cancer cells and the bone microenvironment that can explain the tendency of prostate cancer cells to colonize bone and grow into clinically relevant metastatic deposits. Some studies implicate mechanisms including chemoattraction and enhanced adherence to bone endothelium. Additional data suggest that prostate cancer cells are 'osteomimetic', that is, they take on the properties and behaviors of osteoblasts or osteoclasts upon arrival in bone. These activities lead to enhanced turnover of the bone matrix and may explain the propensity of prostate cancer to grow in bone. Finally, a series of studies have implicated other molecular markers as distinguishing characteristics of bone-metastatic prostate cancer tissue.

Entities:  

Mesh:

Year:  2001        PMID: 11493769     DOI: 10.1097/00042307-200109000-00006

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  15 in total

1.  Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases.

Authors:  Mina J Bissell; Johanne Le Beyec; Robin L Anderson
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

Review 2.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Stephanie Corn; Abraham Schneider; Laurie K McCauley
Journal:  Cancer Treat Res       Date:  2004

3.  [Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Authors:  T Klatte; D Klatte; M Böhm; E P Allhoff
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

Review 4.  Recent advances in bone-targeted therapies of metastatic prostate cancer.

Authors:  Xiyun Deng; Guangchun He; Junwen Liu; Feijun Luo; Xiaoning Peng; Shigang Tang; Zhiyong Gao; Qinlu Lin; Jill M Keller; Tao Yang; Evan T Keller
Journal:  Cancer Treat Rev       Date:  2014-04-16       Impact factor: 12.111

5.  Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002.

Authors:  Matthew B Gretzer; Alan W Partin
Journal:  Rev Urol       Date:  2003

6.  FOXA2 promotes prostate cancer growth in the bone.

Authors:  Zachary M Connelly; Renjie Jin; Jianghong Zhang; Shu Yang; Siyuan Cheng; Mingxia Shi; Justin Mm Cates; Runhua Shi; David J DeGraff; Peter S Nelson; Yunlong Liu; Colm Morrissey; Eva Corey; Xiuping Yu
Journal:  Am J Transl Res       Date:  2020-09-15       Impact factor: 4.060

7.  Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer.

Authors:  Melanie A Simpson; Janet A Weigel; Paul H Weigel
Journal:  Int J Cancer       Date:  2012-02-28       Impact factor: 7.396

8.  Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model.

Authors:  Joy L Kovar; Mark A Johnson; William M Volcheck; Jiyan Chen; Melanie A Simpson
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

9.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.

Authors:  Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

10.  The tumor microenvironment: the making of a paradigm.

Authors:  Isaac P Witz
Journal:  Cancer Microenviron       Date:  2009-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.